IL217922A - Crystalline anhydrate forms of pyridine history, including pharmaceutical preparations and their use in the preparation of pharmaceuticals - Google Patents
Crystalline anhydrate forms of pyridine history, including pharmaceutical preparations and their use in the preparation of pharmaceuticalsInfo
- Publication number
- IL217922A IL217922A IL217922A IL21792212A IL217922A IL 217922 A IL217922 A IL 217922A IL 217922 A IL217922 A IL 217922A IL 21792212 A IL21792212 A IL 21792212A IL 217922 A IL217922 A IL 217922A
- Authority
- IL
- Israel
- Prior art keywords
- medicaments
- preparation
- pharmaceutical compositions
- pyridine derivative
- crystalline anhydrate
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23743509P | 2009-08-27 | 2009-08-27 | |
| PCT/EP2010/062420 WO2011023733A1 (en) | 2009-08-27 | 2010-08-25 | Anhydrate forms of a pyridine derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL217922A0 IL217922A0 (en) | 2012-03-29 |
| IL217922A true IL217922A (en) | 2016-06-30 |
Family
ID=42790943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL217922A IL217922A (en) | 2009-08-27 | 2012-02-02 | Crystalline anhydrate forms of pyridine history, including pharmaceutical preparations and their use in the preparation of pharmaceuticals |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8796269B2 (en:Method) |
| EP (1) | EP2470545B1 (en:Method) |
| JP (3) | JP2013503134A (en:Method) |
| KR (1) | KR20120056258A (en:Method) |
| CN (1) | CN102639536B (en:Method) |
| AU (1) | AU2010288502B2 (en:Method) |
| BR (1) | BR112012003435A2 (en:Method) |
| CA (1) | CA2772168C (en:Method) |
| DK (1) | DK2470545T3 (en:Method) |
| EA (1) | EA021411B1 (en:Method) |
| ES (1) | ES2440938T3 (en:Method) |
| IL (1) | IL217922A (en:Method) |
| IN (1) | IN2012DN01292A (en:Method) |
| MX (1) | MX2012002369A (en:Method) |
| PL (1) | PL2470545T3 (en:Method) |
| SG (1) | SG178231A1 (en:Method) |
| WO (1) | WO2011023733A1 (en:Method) |
| ZA (1) | ZA201200812B (en:Method) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8796269B2 (en) * | 2009-08-27 | 2014-08-05 | Nerre Therapeutics Limited | Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same |
| ES2879375T3 (es) | 2014-06-25 | 2021-11-22 | Univ Emory | Procedimientos de manejo del miedo condicionado con antagonistas del receptor de neuroquinina |
| RS59608B1 (sr) * | 2015-05-18 | 2020-01-31 | Nerre Therapeutics Ltd | Antagonist nk-1/nk-3 receptora za lečenje valunga |
| JP7110197B2 (ja) * | 2016-12-15 | 2022-08-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｎｒｆ２アクチベーター |
| JP7433252B2 (ja) | 2018-03-14 | 2024-02-19 | キャンディ・セラピューティクス・リミテッド | Ｎｋ－１／ｎｋ－３受容体二重アンタゴニストを含む新規な医薬製剤 |
| WO2021030335A1 (en) * | 2019-08-12 | 2021-02-18 | Millendo Therapeutics, Inc. | A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof |
| JP7673064B2 (ja) | 2019-11-15 | 2025-05-08 | カンディー セラピューティクス リミテッド | Ｎｔ－８１４の重要な中間体である６－クロロ－４－（４－フルオロ－２－メチルフェニル）ピリジン－３－アミンを作製するための新規な化学的方法 |
| EP4431512A1 (en) | 2023-03-16 | 2024-09-18 | Bayer Consumer Care AG | Novel dual nk-1/nk-3 receptor antagonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1035115E (pt) * | 1999-02-24 | 2005-01-31 | Hoffmann La Roche | Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1 |
| GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| CA2514037C (en) * | 2003-01-31 | 2012-03-13 | F. Hoffmann-La Roche Ag | Crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-n-methyl-isobutyramide |
| WO2005002577A1 (en) * | 2003-07-03 | 2005-01-13 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
| EP2336136A1 (en) | 2005-09-09 | 2011-06-22 | GlaxoSmithKline LLC | Pyridine derivatives and their use in the treatment of psychotic disorders |
| JP2011506427A (ja) * | 2007-12-11 | 2011-03-03 | シプラ・リミテッド | ゾピクロンおよびその多形相の新規製造方法 |
| GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
| US8796269B2 (en) * | 2009-08-27 | 2014-08-05 | Nerre Therapeutics Limited | Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same |
| JP6342662B2 (ja) * | 2014-01-29 | 2018-06-13 | 京セラ株式会社 | ドリルおよびそれを用いた切削加工物の製造方法 |
-
2010
- 2010-08-25 US US13/389,525 patent/US8796269B2/en active Active
- 2010-08-25 MX MX2012002369A patent/MX2012002369A/es active IP Right Grant
- 2010-08-25 CN CN201080037918.3A patent/CN102639536B/zh active Active
- 2010-08-25 KR KR1020127004865A patent/KR20120056258A/ko not_active Ceased
- 2010-08-25 BR BR112012003435A patent/BR112012003435A2/pt not_active Application Discontinuation
- 2010-08-25 JP JP2012526048A patent/JP2013503134A/ja active Pending
- 2010-08-25 IN IN1292DEN2012 patent/IN2012DN01292A/en unknown
- 2010-08-25 AU AU2010288502A patent/AU2010288502B2/en active Active
- 2010-08-25 SG SG2012007464A patent/SG178231A1/en unknown
- 2010-08-25 EP EP10747619.4A patent/EP2470545B1/en active Active
- 2010-08-25 PL PL10747619T patent/PL2470545T3/pl unknown
- 2010-08-25 ES ES10747619.4T patent/ES2440938T3/es active Active
- 2010-08-25 DK DK10747619.4T patent/DK2470545T3/da active
- 2010-08-25 WO PCT/EP2010/062420 patent/WO2011023733A1/en not_active Ceased
- 2010-08-25 CA CA2772168A patent/CA2772168C/en active Active
- 2010-08-25 EA EA201270302A patent/EA021411B1/ru not_active IP Right Cessation
-
2012
- 2012-02-02 IL IL217922A patent/IL217922A/en active IP Right Grant
- 2012-02-02 ZA ZA2012/00812A patent/ZA201200812B/en unknown
-
2015
- 2015-07-13 JP JP2015139845A patent/JP6404186B2/ja active Active
-
2017
- 2017-06-09 JP JP2017114602A patent/JP2017193564A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2470545A1 (en) | 2012-07-04 |
| IL217922A0 (en) | 2012-03-29 |
| JP2013503134A (ja) | 2013-01-31 |
| KR20120056258A (ko) | 2012-06-01 |
| CN102639536B (zh) | 2015-03-18 |
| JP2017193564A (ja) | 2017-10-26 |
| JP2016000739A (ja) | 2016-01-07 |
| CA2772168C (en) | 2019-01-08 |
| ZA201200812B (en) | 2013-03-27 |
| CN102639536A (zh) | 2012-08-15 |
| US20120157450A1 (en) | 2012-06-21 |
| BR112012003435A2 (pt) | 2016-02-23 |
| PL2470545T3 (pl) | 2014-03-31 |
| EA021411B1 (ru) | 2015-06-30 |
| US8796269B2 (en) | 2014-08-05 |
| CA2772168A1 (en) | 2011-03-03 |
| MX2012002369A (es) | 2012-03-29 |
| AU2010288502A1 (en) | 2012-02-23 |
| IN2012DN01292A (en:Method) | 2015-06-05 |
| ES2440938T3 (es) | 2014-01-31 |
| AU2010288502B2 (en) | 2013-12-12 |
| SG178231A1 (en) | 2012-03-29 |
| WO2011023733A1 (en) | 2011-03-03 |
| EP2470545B1 (en) | 2013-10-09 |
| DK2470545T3 (da) | 2014-01-13 |
| EA201270302A1 (ru) | 2012-07-30 |
| JP6404186B2 (ja) | 2018-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL217490A (en) | History of pyridine-4-il, pharmaceutical preparations containing them and their use in the preparation of medicines | |
| IL213019A (en) | Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them | |
| IL206952A (en) | History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines | |
| IL215065A (en) | Proline derivatives, their preparation process, their pharmaceutical compositions and their uses in drug preparation | |
| IL233282A (en) | Crystalline Forms of 5- (2,6-Di-4-Morpholinyl-4-Pyrimidinyl) -4-Trifluoromethylpyridine-2-Amine Monohydrochloride | |
| IL214309A (en) | Preserved pyridines, pharmaceuticals containing them and their use in the preparation of medicines | |
| IL199945A (en) | Hydrochloric acid derivatives, pharmaceuticals containing them and their use in the preparation of drugs | |
| IL217922A (en) | Crystalline anhydrate forms of pyridine history, including pharmaceutical preparations and their use in the preparation of pharmaceuticals | |
| IL203578A (en) | History of pyrimidine-4 - carboxamide, their preparation and their pharmaceutical preparations | |
| IL217912A (en) | History of 5-Amino-1-Benzimidazole-Pyrazole and Pharmaceutical Preparations Containing It | |
| IL214175A (en) | Derivatives of aminotetralin, their pharmaceutical compositions and their use | |
| IL211391B (en) | Benzo[d] oxazole-2-carboxamido-4-phenyl-thiophene-carboxylate derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments | |
| IL213993A (en) | History of 4,3,2,1-tetrahydropyrido [3,2-b] pyrazine-2-one and pharmaceutical preparations containing them | |
| IL223795A (en) | History of Tetrahydro-Pyrido-Pyrimidine | |
| IL204521A0 (en) | Oxadiazole derivatives, their preparation and pharmaceutical compositions containing them | |
| IL219120A (en) | Cyclohaphtha pyridinyl derivatives and their use in drug preparation | |
| IL214822A0 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
| IL213570A (en) | History 8 - Alkoxy - s - Triazolo [5,1 - a] pyridine and pharmaceutical preparations containing them | |
| IL218490A (en) | Oxazolopyrimidinones dihydro hydroxybencyalkyloxymethyl are converted, preparations containing them and their use in the preparation of pharmaceutical preparations | |
| IL203936A (en) | HISTORY 4 - Pyrimidinsulfamide, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication Preparation | |
| PL2562172T3 (pl) | Pochodne sfelaktonu, ich kompozycje farmaceutyczne, sposoby wytwarzania i zastosowania | |
| IL207972A (en) | History of pyridine-2-ram, pharmaceuticals containing them and their use in the preparation of medicines | |
| IL217500A0 (en) | Tetrazole derivatives, their preparartion and pharmaceutical compositions containing them | |
| IL215285A0 (en) | Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs | |
| IL213983A (en) | Derivatives of pyridazinone that are converted into heteroaryl, their process, their pharmaceutical preparations and their use in the preparation of drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |